Medical Oncologists’ Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study

Abstract

Background Although almost every state medical marijuana (MM) law identifies cancer as a qualifying condition, little research supports MM's use in oncology. We hypothesized that the discrepancy between these laws and the scientific evidence base poses clinical challenges for oncologists. Oncologists' beliefs, knowledge, and practices regarding MM were examined in this study. Methods In November 2016, we mailed a survey on MM to a nationally-representative, random sample of 400 medical oncologists. Main outcome measures included whether oncologists reported discussing MM with patients, recommended MM clinically in the past year, or felt sufficiently informed to make such recommendations. The survey also queried oncologists' views on MM's comparative effectiveness for several conditions (including its use as an adjunct to standard pain management strategies) and its risks compared with prescription opioids. Bivariate and multivariate analyses were performed using standard statistical techniques. Results The overall response rate was 63%. Whereas only 30% of oncologists felt sufficiently informed to make recommendations regarding MM, 80% conducted discussions about MM with patients, and 46% recommended MM clinically. Sixty-seven percent viewed it as a helpful adjunct to standard pain management strategies, and 65% thought MM is equally or more effective than standard treatments for anorexia and cachexia. Conclusion Our findings identify a concerning discrepancy between oncologists' self-reported knowledge base and their beliefs and practices regarding MM. Although 70% of oncologists do not feel equipped to make clinical recommendations regarding MM, the vast majority conduct discussions with patients about MM and nearly one-half do, in fact, recommend it clinically. A majority believes MM is useful for certain indications. These findings are clinically important and suggest critical gaps in research, medical education, and policy regarding MM.

A Population-Based Survey to Assess the Association between Cannabis and Quality of Life among Colorectal Cancer Survivors

“…In a survey of 400 oncology providers practicing across the United States, 70% reported insufficient knowledge to make clinical recommendations about cannabis use in people living with cancer. 13 A survey of 494 health care providers in Washington state found that 64.4% had limited knowledge of cannabis-containing products or where to get them. 14 Conversely, a survey of adult patients with a cancer diagnosis from a state with legalized cannabis found that 75% of respondents would like to have received education about cannabis use from their medical team, but only 15% received information.…”

Attitudes and Beliefs About Medical Usefulness and Legalization of Marijuana among Cancer Patients in a Legalized and a Nonlegalized State

“…This is similar to a survey of medical oncologists who perceived that MM had a lower risk than opioids for addiction, overdose, and death, with 46% recommending marijuana for clinical use. 47 There is limited evidence on the efficacy and toxicities of a combination of marijuana with opioids and other medications, particularly in vulnerable patient populations. More research is needed to understand the role of marijuana for medical purposes as continued interest from patients and families for medical use of marijuana will continue to be elevated in both legal and nonlegal states.…”

Edmonton Symptom Assessment Scale and Clinical Characteristics Associated With Cannabinoid Use in Oncology Supportive Care Outpatients

“…26 However, a nationwide survey among oncologists revealed concerning gaps in data and education, with only 30% of oncologists reporting that they believe they are sufficiently knowledgeable to provide medical marijuana recommendations. 27 Furthermore, there is a dearth of scientific evidence to support cannabinoid use in patients with cancer. Mücke et al 28 conducted a systematic review and meta-analysis to evaluate the therapeutic use of cannabinoids in palliative/ supportive care medicine and concluded that, because of the low quality of evidence, no recommendations can be made regarding the use of cannabinoids in this setting for patients with cancer.…”